ClinicalTrials.gg
CompletedNCT04787380LOVE-HFUpdated Mar 21, 2022

Lancashire Objective Volume Evaluation of Leg Oedema in Heart Failure

An interventional study of Heartfelt device in Heart Failure, sponsored by Heartfelt Technologies. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-21.

Sponsored by Heartfelt Technologies · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 482 studies in Heart Failure with a site in United Kingdom — 100 open to participants now, 127 under way, 18 of them phase 3. Heart Failure · United Kingdom.

Enrollment
251st of 314
27 · median 120
Started
2021
with 24 others
No phase
146 of 482
32 open now
Registered
323rd of 482
by date

Among the 482 studies in Heart Failure with a site in United Kingdom, this one is the 251st largest by enrollment of the 314 interventional ones that give a count, is one of 25 that started in 2021, is one of 146 with no phase, and was the 323rd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

100 of the 482 studies in Heart Failure with a site in United Kingdom are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 482 studies in Heart Failure with a site in United Kingdom, or all of them as a file.
02

Study summary

Patients with heart failure (HF) who recently received treatment with IV diuretics for worsening congestion or outpatients with HF and peripheral oedema treated with at least 80 mg furosemide (or equivalent)/day will be recruited for the LOVE-HF trial at Blackpool Victoria Hospital.

Eligible participants will be randomized to use the Heartfelt Device alongside standard care (weighing + symptom reporting), or standard care alone. Participants and clinicians will be blinded (double blind) as to which arm participants are in, and after 30 days, participants will be crossed over to the other arm. This can be done without disrupting patients as the Heartfelt device can be switched remotely from a 'technical checks only' mode to a 'full data analysis' mode and vice versa. The investigators aim to recruit 30 participants for the pilot study. The study will also run in parallel with its sister pilot trial, LOVE-HF-2.

Through this study, we are testing the capability to get the answers from patients, healthcare systems, and devices, in order to inform future clinical trial design.

Read the detailed description

Heart Failure is the final common pathway of most forms of cardiovascular disease. In the United Kingdom (UK), it affects around 900 000 people, causes or complicates around 5% of adult emergency hospital admissions and consumes up to 2% of total National Health Service (NHS) expenditure. An important part of discharge planning includes measures such as early follow up in order to prevent readmissions. The hallmark of heart failure is fluid retention and between 2009 and 2016, 43% to 50% of hospital admissions were associated with peripheral oedema. Therefore, early recognition of this and treatment of the congestion may prevent hospital admissions. In clinical trials, management strategies have included patient education, telemedicine and remote monitoring. The main non-invasive method for detecting fluid retention has been the use of weight as a surrogate marker.

The Heartfelt device is an invention that uses a system of cameras in a compact device in order to generate 3 dimensional images of the feet and lower legs. The volumes can then be calculated and thus, changes in amount of peripheral oedema can be estimated. In a clinical trial (NCT02993601) performed by the Heart Failure team at the Royal Brompton Hospital, there was good correlation between measurements made by Heartfelt and a water displacement method. The resolution was as good as 20mls.

By positioning the Heartfelt device in the bedroom, automatic measurements can be made whenever the subject gets in and out of bed. Images are only taken of the specified subject. Data is censored so that the part of the body which is 50cm above the floor is not stored. Encrypted, anonymised data is transmitted over the internet to the company's secure servers. Personal identifiable data (participant name, address, age...) is stored on an encrypted hard drive, along with linkage information (device serial numbers) to associate the participant identifiable data with the data captured in the home. Therefore, data collection is not only secure but entirely passive, which is a major advantage compared with previous non-invasive methods and it is applicable to a very wide range of compliant and non-compliant patients.

Our hypothesis is that the Heartfelt device can directly detect the increase in peripheral oedema associated with heart failure decompensation and that, on average, the number of days with missing data collected by the Heartfelt device will be lower than that of the weighing scales.

Blackpool Victoria Hospital provides acute heart failure service both for in-patients and out-patients, including capacity to administer parenteral furosemide in hospital cardiac day case unit, community or home settings.

Participants with chronic heart failure will be monitored in their home using the Heartfelt device (experimental arm only). Participants in both arms will also receive standard care. "Standard care" means that participants will be encouraged to report symptoms and weigh themselves on a regular basis (as per the recommendation of their doctor or heart failure nurse) reporting them without delay. This will be done in line with current advice given to heart failure patients locally, which is that patients should record their weight in a diary and seek urgent medical attention if their weight goes up by at least 2 to 3 pounds in 24 hours, or 5 pounds or more in one week, or if they notice an increase in leg swelling and/or an increase in breathlessness.

Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per the usual advice given to patients, thus taking part in the study should not change their behaviour. Temporal changes in weight and volume will be compared. Research questionnaires will also be used to estimate the quality of life, mental wellbeing and hope status of participants and collect feedback on the device and study design.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart Failure
  • Edema Leg
  • Quality of life
  • Hospital Admissions
  • Days alive out of hospital
  • Heartfelt Device
  • Artificial Intelligence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with HF who recently (\<6 months) received treatment with IV diuretics for worsening congestion or outpatients with HF and peripheral oedema (any degree) treated with at least 80 mg furosemide (or equivalent)/day.
  • Patients with HF ≥18 years.

    • Note that the research team will try to include as many patients as possible in the month following discharge, however we will not exclude consideration of a small proportion of patients within 6 months of decompensation. This has the extra advantage of demonstrating value of the device beyond 1-2 months of decompensation.

Exclusion criteria

Exclusion Criteria:

  1. Inability to provide *
  2. Participant has bandages to lower limbs everyday
  3. Participant has an amputation of the foot
  4. Participant is a regular wheelchair user
  5. Participant is of no fixed abode
  6. Participant has potentially reversible cause of decompensated heart failure and is awaiting urgent intervention (revascularisation/ valvular heart disease), which means the patient cannot be discharged for home-based care.
  7. Participant is taking part in a conflicting evaluation/study that could confound the results of this evaluation by and/or impact clinical interventions and participant outcomes.
  8. Participant must not be pregnant, and is taking relevant if of *

    • Note that a participant not able to comply with weighing is NOT an exclusion criteria as the Heartfelt Device should provide data for these participants despite their lack of ability to adhere to the usual monitoring protocol, and this is seen as one of the long term benefits that the device can provide.
    • Note that the exclusion criteria (a) has been added as participants would need to be able to give individual responses to questionnaires, communicate directly with the Heartfelt team, etc.
    • Note that the exclusion criteria (h) has been requested by the insurance for clinical trial cover.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    LOVE-HF Arm A (Full data analysis mode of Heartfelt + weight + symptoms reporting)

    Participants in LOVE-HF Arm A (Full data analysis mode of Heartfelt + weight + symptoms reporting) will not know if they are assigned to LOVE-HF Arm A or LOVE-HF Arm B. The Heartfelt device will be in 'full data analysis' mode and participants will follow standard care recommendations for weighing themselves and reporting their symptoms. 'Full data analysis' mode means that the device will be fully operational and will be detecting and reporting changes in foot volume over time. The device will have been allocated to the 'full data analysis' mode prior to shipping. Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per usual advice given to patients, thus taking part in the study should not change their behaviour.

    Device: Heartfelt device

  • No intervention
    LOVE-HF Arm B (Technical checks only mode of Heartfelt + weight + symptoms reporting)

    Participants in LOVE-HF Arm B (Technical checks mode of Heartfelt + weight + Symptoms reporting) will not know if they are assigned to LOVE-HF Arm A or LOVE-HF Arm B. The Heartfelt device will be in 'technical checks only' mode where the data analysis pipeline is blocked and changes in foot volume over time will not be processed or reported. However, technical checks on device functioning and image quality (e.g. camera being blocked) will be made as usual. The device will have been allocated to the 'technical checks only' mode prior to shipping. Participants will follow standard care recommendations for weighing themselves and reporting their symptoms. Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per usual advice given to patients, thus taking part in the study should not change their behaviour.

Interventions

  • DeviceHeartfelt device

    The Heartfelt device uses a system of cameras in a compact device to generate 3D images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit; however, given the COVID-19 pandemic, only the free standing option will be available to participants, so as to avoid the necessity of an installer visiting the patient. For the measurements to take place, the participant walks in the field of view of the device. Participants are not expected to change anything to their routine. The device can also take measurements in the dark. The switch between 'full data analysis' and 'technical checks only' modes can be done remotely, making the cross-over seamless. In the event that an alert is generated by the device, a medical assessment will take place either by phone or face to face appointment to evaluate the participant's condition.

06

What researchers measure

Primary outcomes

  1. Proportion of participants we can establish number of days alive out of hospital

    The proportion of participants for whom we can collect data to establish the number of days alive and out of hospital.

    Time frame: 60 days

Secondary outcomes

  1. Proportion of participants we can establish number of days alive and well out of hospital

    Proportion of participants for whom we can safely collect data using the study protocol to establish number of days alive out of hospital in which the participant reports feeling well.

    Time frame: 60 days

  2. Proportion of participants who complete study questionnaires

    Proportion of participants who complete the questionnaires to assess Mental Wellbeing Score, hopelessness, and satisfaction to service provided.

    Time frame: 60 days

  3. True alerts - oedema

    Proportion of "true alerts" corresponding to "increase in oedema".

    Time frame: 60 days

  4. True alerts - diuretics

    Proportion of "true alerts" corresponding to "increase in diuretics".

    Time frame: 60 days

  5. Proportion of participants we can establish date of emergency hospital admission which is HF related

    Proportion of participants for whom we can safely collect data using the study protocol to establish the date of emergency hospital admissions related to HF

    Time frame: 60 days

  6. Proportion of participants we can establish date of emergency hospital admission due to any cause

    Proportion of participants for whom we can safely collect data using the study protocol to establish the date of emergency hospital admission due to any cause.

    Time frame: 60 days

  7. Proportion of participants we can establish date of planned hospital admission which is HF related

    Proportion of participants for whom we can safely collect data using the study protocol to establish the date of planned hospital admissions related to HF

    Time frame: 60 days

  8. Proportion of participants we can establish date of planned hospital admission due to any cause

    Proportion of participants for whom we can safely collect data using the study protocol to establish the date of planned hospital admission due to any cause.

    Time frame: 60 days

  9. Proportion of participants we can establish date of death

    Proportion of participants in the study for whom the date of death can be established.

    Time frame: 60 days

  10. Proportion of participants we can establish cause of death

    Proportion of participants in the study for whom the cause of death can be established.

    Time frame: 60 days

  11. Proportion of participants we can establish their quality of life

    Proportion of participants for whom we can safely collect data using the study protocol to establish participant quality of life.

    Time frame: 60 days

  12. Proportion of participants we can establish symptom reporting

    Proportion of participants for whom we can safely collect data using the study protocol to establish symptom reporting.

    Time frame: 60 days

Other outcomes

  1. Proportion of participants we can establish the number of days alive out of hospital in which the participant had significant weight gain

    Proportion of participants for whom we can collect data using the study protocol to establish the number of days alive out of hospital in which the participant had a significant increase of weight (including both paper diary records and the provided Bluetooth scales).

    Time frame: 60 days

  2. Proportion of participants we can establish the number of days alive out of hospital in which the device did not capture adequate images of the foot to generate a volume

    Proportion of participants for whom we can safely collect data using the study protocol to establish the number of days alive out of hospital in which the Heartfelt device did not capture high enough quality images of the participant's foot to generate a volume.

    Time frame: 60 days

07

Study locations

1 site
  • Department of Cardiology, Lancashire Cardiac Centre, Blackpool Teaching Hospitals NHS Foundation Trust (Blackpool Victoria Hospital), Whinney Heys Road.
    Blackpool, Lancashire FY3 9NR, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Sep 2021, 6 months.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's 6 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2021
First posted
Mar 8, 2021
StartActual
Mar 5, 2021
Primary completionActual
Sep 30, 2021
CompletionActual
Sep 30, 2021
Last update
Mar 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04787380
Lead sponsor
Heartfelt Technologies
Collaborators
Blackpool Teaching Hospitals NHS Foundation Trust
Responsible party
Sponsor
First posted
Mar 8, 2021
Start date
Mar 5, 2021
Primary completion
Sep 30, 2021
Completion
Sep 30, 2021
Last update
Mar 21, 2022

Study contacts

Kenneth Wong, MA, DM, FRCP
principal investigator · Blackpool Teaching Hospitals NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion